MedTrace Logo

Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control

NCT07244003 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 430

Last updated 2025-11-24

No results posted yet for this study

Summary

The main objective of this study is to compare the efficacy and safety of the triple combination therapy of Met/SGLT-2i/GLP-1RA or other oral antidiabetic drugs in patients with type 2 diabetes exhibiting poor glycemic control.

Conditions

  • T2DM (Type 2 Diabetes Mellitus)

Interventions

DRUG

Metformin

The dosage of metformin hydrochloride was consistent with baseline.

DRUG

Triple Therapy of Other Oral Antidiabetic Drugs

The dosage of metformin hydrochloride was consistent with baseline. The usage and dosage of other hypoglycemic drugs were referred to their respective instructions.

DRUG

ganagliflozin

Ganagliflozin tablet : 50mg/d.

DRUG

liraglutide

Liraglutide injection: 0.6 mg/d for the first week, 1.2 mg/d for the second week, and 1.8 mg/d after the third week.

Sponsors & Collaborators

  • Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-29
Primary Completion
2027-12-31
Completion
2028-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07244003 on ClinicalTrials.gov